Quantitative Analysis of Multiphase Contrast-Enhanced CT Images: A Pilot Study of Preoperative Prediction of Fat-Poor Angiomyolipoma and Renal Cell Carcinoma

American Journal of Roentgenology, Ahead of Print.
Source: American Journal of Roentgenology - Category: Radiology Authors: Source Type: research

Related Links:

Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
Authors: Wang Q, Zhang H, Chen Q, Wan Z, Gao X, Qian W Abstract The kidney renal clear cell carcinoma (KIRC) with poor prognosis is the main histological subtype of the renal cell carcinoma, accounting for 80-90% of patients. Currently, the N6-methyladenosine (m6A) epitranscriptional modification draws much attention. The m6A RNA modification, the most plentiful internal modification of mRNAs and noncoding RNAs in the majority of eukaryotes, regulates mRNAs at different levels and is involved in disease occurrence and progression. The GTExPortal and TCGAportal were applied to investigate the METTL14 mRNA expression...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Conclusion: XGP is a diagnostic and therapeutic dilemma. Partial Nephrectomy may be appropriate in management of XGP in select cases. PMID: 31976820 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
Conclusions: Adrenal SBRT for oligometastatic disease is a feasible, noninvasive option with excellent LC and minimal toxicity. Lesions in close proximity to radiosensitive organs may benefit from dynamic patient positioning and selective simultaneous-integrated boost techniques to allow for dose escalation, while also limiting toxicity risks.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Endocrine Source Type: research
Authors: Ungari M, Trombatore M, Ferrero G, Gusolfino MD, Manotti L, Tanzi G, Varotti E, Bertoni R Abstract A case of a patient with type 2 papillary renal cell carcinoma with eosinophilic cytoplasmatic inclusions is presented. About 50% of tumor cells were characterized by a well-circumscribed intra-cytoplasmatic round-to-oval or irregular inclusion/globule. Inclusions were 7-30 micron in diameter. They were glassy and pale to slightly eosinophilic in color in hematoxylin and eosin, were stained red by trichrome and were negative for periodic acid-Schiff reaction. Immunohistochemically, globules were negative for ...
Source: Pathologica - Category: Pathology Tags: Pathologica Source Type: research
CONCLUSION: These results revealed that MTDH may be a prognostic metastatic biomarker of ccRCC that promotes ccRCC metastasis by activating SND1-mediated the ERK and EMT signaling pathways. MTDH may serve as an anti-tumor therapeutic target that can be applied for the clinical treatment of metastatic ccRCC. METHODS: MTDH/SND1 mRNA expression in clear cell renal cell carcinoma (ccRCC) was comprehensively estimated by analysis of GEO-ccRCC and TCGA-KIRC datasets with R software and packages. MTDH protein expression was assessed in a total of 111 ccRCC patients from Peking University First Hospital by immunohistochemistr...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Conclusion: M6A RNA methylation regulators play important roles in the initiation and progression of ccRCC and provide a novel sight to understand m6A RNA modification in ccRCC.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Clear-cell renal cell carcinoma (ccRCC) is the most common and lethal subtype of kidney cancer. VHL and PBRM1 are the top two significantly mutated genes in ccRCC specimens, while the genetic mechanism of the VHL/PBRM1-negative ccRCC remains to be elucidated. Here we carried out a comprehensive analysis of single-cell genomic copy number variations (CNVs) in VHL/PBRM1-negative ccRCC. Genomic CNVs were identified at the single-cell level, and the tumor cells showed widespread amplification and deletion across the whole genome. Functional enrichment analysis indicated that the amplified genes are significantly enriched in ca...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Abstract OBJECTIVES: To assess the diagnostic accuracy of signal loss on In-Phase (IP) Gradient-Echo (GRE) images for differentiation between Renal Cell Carcinomas (RCCs) and Lipid-Poor Angiomyolipomas (lpAMLs). METHODS: We retrospectively searched our institutional database for histologically-proven small RCCs (
Source: The British Journal of Radiology - Category: Radiology Authors: Tags: Br J Radiol Source Type: research
CONCLUSION: This real-world study found a median OS of 52 months for patients with favorable IMDC risk treated with first-line sunitinib, setting a new benchmark on clinical outcomes of clear cell mRCC. Analysis of intermediate risk group by one or two risk factors demonstrated distinct clinical outcomes. IMPLICATIONS FOR PRACTICE: This analysis offers a contemporary benchmark for overall survival (median, 52.1 months; 95% confidence interval, 43.4-61.2) among patients with clear cell metastatic renal cell carcinoma who were treated with sunitinib as first-line therapy in a real-world setting and classified as favorab...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Radiology | Renal Cell Carcinoma | Study